Benefits of Treatment with CDK4/6 Inhibitors in HR+/HER2- aBC in Clinical Trials and the Real World

Speciality: Oncology

Description:

Welcome, viewers! In this insightful presentation, Dr. Shailesh Bondarde, a renowned oncologist, delves into the transformative role of CDK4/6 inhibitors in managing hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (aBC). Drawing from robust clinical trial data and real-world evidence, Dr. Bondarde highlights how these targeted therapies have reshaped treatment paradigms, offering hope and extended survival to countless patients.

Clinical trials have consistently demonstrated that CDK4/6 inhibitors, when combined with endocrine therapy, significantly improve progression-free survival (PFS) and overall survival (OS) in HR+/HER2- aBC. Landmark studies such as PALOMA, MONARCH, and MONALEESA have shown reduced disease progression by nearly 50% and extended median OS by years, even in high-risk subgroups. These agents also exhibit manageable toxicity profiles, enabling prolonged treatment adherence. Beyond trials, real-world evidence corroborates these benefits, with observational studies reporting improved quality of life, delayed chemotherapy use, and enhanced survival rates across diverse populations, including older adults and those with visceral metastases.

As we conclude, Dr. Bondarde emphasizes integrating CDK4/6 inhibitors into standard care while addressing challenges like accessibility and cost. Their efficacy in controlled trials and real-world practice underscores their value as a cornerstone of HR+/HER2- aBC management. Stay tuned to explore more groundbreaking insights in oncology, and don’t forget to subscribe for updates on upcoming videos. Thank you for watching!

See More Webinars @ Hidoc Webinars